Page last updated: 2024-12-05

2-norbornene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-Norbornene is a bicyclic alkene with the molecular formula C7H10. It is a colorless liquid with a pungent odor. 2-Norbornene is a versatile starting material for the synthesis of a wide range of organic compounds. It is particularly useful in the synthesis of polymers, pharmaceuticals, and other fine chemicals. 2-Norbornene is also used as a reagent in organic chemistry reactions, such as the Diels-Alder reaction. It has been studied extensively due to its unique chemical structure and reactivity. Studies have explored its use in various applications, including its potential as a monomer for the production of high-performance polymers and its role in the development of new synthetic methodologies.'

norbornene : A bridged compound that is cyclohexane with a methylene bridge between carbons 1 and 4 and a double bond at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10352
MeSH IDM0133622

Synonyms (25)

Synonym
2-norbornylene
bicyclo[2.2.1]hept-2-ene
norbornylene
nsc120425
norcamphene
bicyclo[2.2.1]heptene
wln: l55 a cutj
2-norbornene
norbornene
498-66-8
nsc-120425
nsc-22453
nsc22453
bicyclo[2.2.1]-2-heptene
nsc 120425
N0166
AKOS009157173
FT-0613233
bicyclo [2.2.1] hept-2-ene
bicyclo[2,2,1]-2-heptene
DTXSID2022042
Q420176
AMY10401
E78935
EN300-54688

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" This radiolabelled compound exhibits both high bioavailability and metabolic stability with approximately 90% remaining intact up to 30 min following administration."( Synthesis and evaluation of an 18F-labelled norbornene derivative for copper-free click chemistry reactions.
Knight, JC; Richter, S; Way, JD; Wuest, F; Wuest, M, 2013
)
0.39

Dosage Studied

ExcerptRelevanceReference
"The dosage of INH and RIF is minimal in the combination form with the NOR nanoparticles compared to the plain INH and RIF."( Enhancing antimycobacterial activity of isoniazid and rifampicin incorporated norbornene nanoparticles.
Kumarasingam, K; Mane, SR; Shunmugam, R; Sivakumar, S; Uma Devi, KR; Vincent, M,
)
0.13
"Low dosage of INH and RIF along with NOR nanocarrier has similar activity to that of INH and RIF; thus this is expected to reduce adverse effects and NOR did not alter the functional activity of INH and RIF, thus becoming eligible for the newer drug carrier in TB treatment."( Enhancing antimycobacterial activity of isoniazid and rifampicin incorporated norbornene nanoparticles.
Kumarasingam, K; Mane, SR; Shunmugam, R; Sivakumar, S; Uma Devi, KR; Vincent, M,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (86)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (2.33)18.7374
1990's0 (0.00)18.2507
2000's3 (3.49)29.6817
2010's50 (58.14)24.3611
2020's31 (36.05)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.12 (24.57)
Research Supply Index4.48 (2.92)
Research Growth Index5.94 (4.65)
Search Engine Demand Index38.14 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.15%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other86 (98.85%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]